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Preface 
This thesis is presented in option I of the dissertation guidelines, the publication-
ready format. The manuscript will be submitted to the South African Medical Journal 
for publication. A letter to the Editor will accompany the manuscript explaining the 
need for more than 15 references (as it exceeds the publication guidelines). The 
references cited are important as the study findings may potentially impact clinical 
services in the public health sector in South Africa.  
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Screening for Retinopathy of Prematurity (ROP) is recommended to prevent possible 
blindness. Prior to 2016, resource limitations precluded routine ROP screening at 
Groote Schuur Hospital (GSH). Previous pilot studies at GSH did not detect ROP 
requiring treatment. However, improved survival of very low birth weight infants 
may affect the prevalence of ROP. 
Objectives 
The study objectives were to: i) Determine the prevalence and severity of ROP in a 
prospective cohort of premature infants; ii) Describe the association with pre-
specified potential risk factors; iii) Assess the feasibility of screening for ROP in our 
resource-limited setting. 
Methods 
Infants with a birth weight of < 1251 g or gestational age < 31 weeks admitted to the 
GSH neonatal unit from November 2012 to May 2013 were screened. A paediatric 
ophthalmologist examined the infants at 4 weeks chronological age or 32 weeks 
corrected gestational age, with follow-up examinations as indicated. 
Results 
Screening was performed in 135 of 191 eligible infants. A total of 313 ROP 
examinations were performed; 38.5% of infants required a single examination and 
16.3% required more than four. The mean gestational age and weight at birth were 
30.1 ± 1.9 weeks and 1056 ± 172 g respectively. Seventy-four infants were female 
(54.8%). Only black (57.0%) and coloured (42.9%) infants were represented. ROP was 
diagnosed in 40 (29.6%) infants: Eight (5.9%) infants had clinically significant ROP. No 
infants had stage 4 or 5 ROP. No infants weighing more than 1250 g required 
treatment. Two infants received laser treatment. Infants with ROP had a lower mean 
gestational age and lower mean birth weight than those without ROP: 29.2 ± 1.6 vs. 
30.5 ± 1.9 weeks (P < 0.002) and 988 ± 181 g vs. 1085 ± 160 g (P = 0.001) 
respectively. Infants with ROP were more likely to have received a blood transfusion 
(P < 0.002); to have late onset sepsis (P = 0.024); and to have received exclusive 
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breast milk feeds (P = 0.005). There were no significant differences in the level of 
respiratory support, the need for oxygen therapy, the occurrence of apnoea, early 
sepsis or severe intraventricular haemorrhage in infants with ROP compared to no 
ROP.  
On multivariate analysis, only gestational age was independently associated with 
ROP was gestational age (RR 0.85; 95% CI 95% 0.740-0.988; p=0.03). When 
gestational age was excluded in post-hoc analysis, birth weight (RR 0.99; 95% CI 
0.997-0.999; P=0.03) and blood transfusions (RR 1.71; 95% CI 1.027-2.859; P=0.03) 
were independently associated with ROP. Infants <1000 g had a 2.5 times higher risk 
of having ROP than their larger counterparts (95% CI 1.05-5.90, P=0.03). ROP 
screening was completed in 91.1% (123/135) of infants. 
Conclusion 
Clinically significant ROP was found in this study. In contrast to previous studies 
conducted in this setting, two patients received laser treatment. Extensive resources 
were required for successful screening. The strong association with birth weight and 
gestational age suggests that infants with lower birth weights and gestational ages 
should be prioritized for screening in our resource limited setting.  
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Chapter 1: Introduction 
1.1. Context 
Retinopathy of prematurity (ROP) is a well-described preventable cause of visual 
impairment and blindness in premature infants.[1] It is a multifactorial 
vasoproliferative condition that affects the immature retina of premature infants. 
ROP was first described in 1942 when surviving premature infants were noted to 
have a high incidence of blindness.[2] The role of oxygen therapy in the development 
of ROP was described in the 1950’s.[3] This resulted in the more judicious use of 
oxygen, with a decrease in ROP. Low gestational age, low birth weight and prolonged 
oxygen exposure are risk factors for developing ROP.[1,4,5] Fluctuations in 
administered oxygen concentration also contribute to the development of ROP. 
Markers of the severity of neonatal illness such as the need for mechanical 
ventilation, blood transfusions, the presence of a patent ductus arteriosus, sepsis, 
significant intraventricular haemorrhage or poor post-natal weight gain have been 
described with an increased risk of developing ROP.[6] Furthermore, a genetic 
predisposition to the development of ROP may play a role.[7] As neonatal care 
advanced, infants with lower gestational ages and birth weights survived. 
Subsequently, the incidence of ROP increased, hence the ‘second epidemic’ noted in 
the 1960’s. More recently, a ‘third epidemic’ of ROP has been described in middle-
income countries with a combination of small premature infants, as well as larger 
more mature infants developing ROP. This has been attributed to a greater number 
of premature infants surviving due to improved neonatal care, but lack adequate 
monitoring when receiving oxygen therapy.[8,9] 
Globally, 50 000 children have blindness secondary to ROP.[10] In resource rich 
countries the incidence is between 6-18% mainly affecting infants born at less than 
32 weeks gestational age and less than 1250 g. In middle-income countries, the 
incidence ranges from 8-38%, with infants with a gestational age at birth of greater 
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than 32 weeks also affected. Figures for sub-Saharan Africa, with the exception of 
South Africa, are quoted at 0%.[10] The absence of ROP is ascribed to limited 
resources for healthcare with high neonatal and infant mortality rates. In South 
Africa, studies at several public institutions from 1991 to 2013 have found incidences 
of ROP ranging from 18.6-24%.[11-15] 
Screening and early treatment is important to prevent morbidity related to this 
condition. The ROP Working Group of South Africa has recommended guidelines for 
the prevention, screening and treatment of ROP for South Africa, based on 
international guidelines.[16] The United South African Neonatal Association (USANA), 
the Ophthalmological Society of South Africa and the South African Vitreoretinal 
Society have endorsed these recommendations, but resource limitations are 
acknowledged as a limiting factor in implementation of these guidelines.[16]  
The Groote Schuur Hospital (GSH) neonatal unit provides tertiary level care for over 
500 very low birth weight (VLBW) and extremely low birth weight (ELBW) premature 
infants per year. A study at GSH in 1991 by Straker and van der Elst,[11] as well as an 
unpublished study in 2001 (MMed thesis) reported low rates of ROP and did not 
detect any ROP requiring treatment.[11,17] Based on these findings and resource 
constraints, an ROP screening service was not instituted. However, more recent data 
from other tertiary institutions in South Africa suggests cause for concern. A 2006 
study at Chris Hani Baragwanath Hospital found that 16.3% of VLBW had ROP, with 
1.6% of infants requiring treatment.[14] Mayet et al. stated that the findings were 
likely to be an underestimate as a high number of the study cohort was lost to follow 
up before complete vascularization of the retina was achieved. The authors 
speculated that 2.9% of the cohort would have severe ROP. No infants with a birth 
weight of more than 1250 g required treatment for ROP in this study. In 2002, a 
study at Kalafong Hospital in Pretoria by Delport et al. reported an incidence of 
24.5% ROP, with 4.3% of infants less than 1500 g reaching threshold ROP.[13] The 
incidence of threshold ROP in infants weighing less than 1251 g was 3.2%. A 1995 
study at Tygerberg Children’s Hospital showed a prevalence of ROP of 31.1% with 
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7.1% of infants developing severe ROP.[12] In 2013, van der Merwe et al. from 
Tygerberg Children’s Hospital reported an ROP prevalence of 21.8%, with clinically 
significant ROP in 4.4% of the cohort.[15]  Six infants (1.5%) in this study received laser 
treatment. These studies all reported higher incidences of ROP than previously 
found at GSH. Based on this data, we secured funding to conduct a six month pilot 
study with the following aims: 1) determine the prevalence and severity of ROP in a 
prospective cohort of preterm infants; 2) describe the association of pre-specified 
potential risk factors; and 3) to assess the feasibility of screening for ROP in a 




Written informed parental consent was obtained for both the screening 
examination, as well as inclusion into the study. The consent form, information on 
ROP and the screening examination was made available to parents in English, 
Afrikaans and Xhosa. Consent for ROP screening was obtained from the medical 
superintendent for abandoned infants and infants who were being placed for 
adoption. Parents who refused consent for the study were offered ROP screening for 
their infants without inclusion into the study. 
 
Medical management 
Infants delivered at less than 30 weeks gestation or with an estimated foetal weight 
of less than 1200 g were placed in a plastic bag after birth to prevent hypothermia. 
The International Liaison Committee on Resuscitation (ILCOR) guideline (2010) was 
followed. Infants with respiratory distress received CPAP or intermittent positive 
pressure ventilation via T-piece resuscitator and/or endotracheal intubation if 
required in the delivery room. Blended oxygen was utilised in the neonatal unit.  
Infants were monitored with pulse oximetry, targeting saturations of 88-92%. 
Standardised protocols were followed for the administration of surfactant and blood 
transfusions. Exclusive breast milk feeds were encouraged for all infants – donor 
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breast milk was variably available to infants weighing less than 1200 g, as per unit 
policy at the time. Cranial ultrasounds were performed in the first week of life and 
repeated at discharge, or earlier if indicated.  
 
Screening ophthalmic examination 
A paediatric ophthalmologist performed ROP examinations once a week. A clinician 
reviewed the neonatal unit’s admissions book daily to identify eligible infants. A 
register and diary was kept to facilitate the timing of examinations.  
 
The first ophthalmology examination occurred at 4 weeks chronological age or at 32 
weeks corrected gestational age, whichever occurred later. After the initial 
screening, follow up was scheduled according to standard guidelines described 
below. If infants were clinically unstable at the time scheduled for screening or 
follow up, the examination was deferred until the clinical condition improved. A 
research assistant was employed for the duration of the study.  
Two milligrams of Cyclopentolate hydrochloride and 10mg phenylephrine 
hydrochloride (Cyclomydril®) drops were instilled into each eye in preparation for 
screening; one drop per eye every 15-20 minutes commencing approximately 45-60 
minutes prior to eye examination until pupils were dilated (up to a maximum of 3 
drops per eye). Benoxinate hydrochloride 0.4% was used for local anaesthetic. The 
nasolacrimal duct was compressed for 3 minutes after insertion of the eye drops to 
limit systemic absorption. The lights in the area were dimmed at the time of 
insertion of eye drops to limit discomfort to infants. Inpatients were monitored as 
per standard practice in the neonatal unit. Outpatients received limited clinical 
observation and were discharged once they successfully fed post examination. 
Infants were swaddled and nested during the ophthalmology examination. A 24% 
oral sucrose solution was placed in the mouth of infants at the start of the 
examination to provide analgesia. The infants’ retinas were examined by binocular 
indirect ophthalmoscopy using a 28 dioptre condensing lens, with a lid retractor and 
scleral indentation in order to visualize the ora serrata.   
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Follow up of ROP 
Follow up was according to standard guidelines listed below[18]: 
≤ 1-week follow-up 
 Stage 1 or 2 ROP in zone I
 Stage 3 ROP in zone II
1 to 2 week follow up 
 Immature vascularization in zone I (no ROP)
 Stage 2 ROP in zone II
 Regressing ROP in zone II
2 week follow up 
 Stage 1 ROP in zone II
 Regressing ROP in zone II
2 to 3 week follow up 
 Immature vascularization in zone II (no ROP)
 Stage 1 or 2 ROP in zone III
 Regressing ROP in zone III
All infants who required follow up were booked in a ROP diary. If infants were 
transferred, the receiving hospitals were informed that the screening process 
needed to be completed. Infants who were discharged home had appropriate follow 
up appointments made and communicated to parents. The appointment dates were 
documented on a hospital appointment card and in the Road to Health booklet. The 
research assistant reminded parents telephonically 3 days prior to the appointment. 
If infants did not arrive for appointments, parents were telephoned with a new 
appointment date for the next session. If the three consecutive appointments were 
missed, no further attempts to contact the parents were made. If a healthcare 
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worker or parent contacted the research assistant after missing appointments, the 
infant was scheduled for the next screening session.  
 
Infants were discharged from screening if one of the following findings were 
observed[16]: 
 Zone III retinal vascularisation attained without previous zone I or II ROP (if 
the gestational age was < 35 weeks further examinations were considered) 
 Full retinal vascularisation present 
 Gestational age of 45 weeks and no pre-threshold disease (stage 3 ROP in 
zone II, any ROP in zone I) or worse ROP is present 
 Regression of ROP (no abnormal vascular tissue present) 
 
Initial and subsequent follow up was done at the GSH neonatal unit. Infants 
requiring prolonged follow up were reviewed at the outpatient clinic of the 
Ophthalmology Department at the Red Cross War Memorial Children’s Hospital. A 
maximum of 20 patients were booked per session. 
 
Treatment of ROP 
Treatment was performed according to the Early Treatment for Retinopathy of 
Prematurity Randomized Trial (ETROP) guidelines, and was initiated for the following 
findings[19]: 
 Zone I ROP: any stage with plus disease 
 Zone I ROP: stage 3, no plus 
 Zone II ROP: stage 2 or 3 with plus disease 
 
Plus disease was defined as the degree of dilation and tortuosity of the posterior 
retinal blood vessels as defined by standard criteria.  
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A retinal specialist was available to deliver laser treatment within 72 hours of 
diagnosis to minimize the risk of retinal detachment. Treatment took place in the 
GSH neonatal unit, where a dedicated laser machine was housed for the duration of 
the study. 
1.2. Ethical considerations 
This study was approved by the University of Cape Town Health Sciences Faculty 
Human Research Ethics Committee and conforms to the principles of the 2013 
Declaration of Helsinki. 
Screening for ROP is a standard of care in adequately resourced neonatal units caring 
for premature infants and is a routine examination the in private health sector in 
South Africa. In this pilot study, all infants fulfilling the inclusion criteria were eligible 
for screening and informed written parental consent was obtained prior to 
examination. Parents were offered screening for their infants if they chose not to 
consent to inclusion into study. Despite being informed of the potential benefits, one 
parent refused consent for ROP screening. The medical superintendent gave consent 
for screening of infants who had been abandoned or were being placed for adoption. 
HREC number 509/2012 
1.3. Author guidelines 
The publication ready manuscript will be submitted to the South African Medical 
Journal. This journal was chosen for publication, as the research is applicable to the 
public service health care setting in South Africa. This work motivates for the use of 
stricter criteria for retinopathy of prematurity screening in a tertiary hospital setting 
where resource limitations may otherwise prevent an effective ROP screening 
program. It differs from a recently published guideline for the prevention, screening 
and treatment of ROP, which may not be feasible to implement and sustain in South 
Africa’s tertiary referral setting.[16] 
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Author Guidelines 
Accepted manuscripts that are not in the correct format specified in these guidelines 
will be returned to the author(s) for correction, and will delay publication. 
Authorship 
Named authors must consent to publication. Authorship should be based on: (i) 
substantial contribution to conception, design, analysis and interpretation of data; 
(ii) drafting or critical revision for important intellectual content; or (iii) approval of
the version to be published. These conditions must all be met (uniform requirements 
for manuscripts submitted to biomedical journals; refer to www.icmje.org). 
Conflict of interest 
Authors must declare all sources of support for the research and any association 
with a product or subject that may constitute conflict of interest. 
Research ethics committee approval 
Provide evidence of Research Ethics Committee approval of the research where 
relevant. 
Protection of patient's rights to privacy 
Identifying information should not be published in written descriptions, 
photographs, and pedigrees unless the information is essential for scientific 
purposes and the patient (or parent or guardian) gives informed written consent for 
publication. The patient should be shown the manuscript to be published. Refer to 
www.icmje.org. 
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Ethnic classification 
References to ethnic classification must indicate the rationale for this. 
 
Manuscripts 
Shorter items are more likely to be accepted for publication, owing to space 
constraints and reader preferences. 
Research articles (previously 'Original articles') not exceeding 3 000 words, with up 
to 6 tables or illustrations, are usually observations or research of relevance to 
clinical medicine and related fields. References should be limited to no more than 15. 
Please provide a structured abstract not exceeding 250 words, with the following 
recommended headings: Background, Objectives, Methods, Results, and Conclusion. 
Scientific letters will be considered for publication as shorter Research articles.  
Editorials, Opinions, etc. should be about 1000 words and are welcome, but unless 
invited, will be subjected to the SAMJ peer review process. 
Review articles are rarely accepted unless invited. 
Letters to the editor, for publication, should be about 400 words with only one 
illustration or table, and must include a correspondence address. 
Forum articles must be accompanied by a short description (50 words) of the 
affiliation details/interests of the author(s). Refer to recent forum articles for 
guidance. Please provide an accompanying abstract not exceeding 150 words. 
Book reviews should be about 400 words and must be accompanied by the 
publication details of the book. 
Obituaries should be about 400 words and may be accompanied by a photograph. 
Guidelines must be endorsed by an appropriate body prior to consideration and all 
conflicts of interest expressed. A structured abstract not exceeding 250 words 
(recommended sub-headings: Background, Recommendations, Conclusion) is 
required. Sections and sub-sections must be numbered consecutively (e.g. 1. 
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Introduction; 1.1 Definitions; 2. etc.) and summarised in a Table of Contents. 
References, appendices, figures and tables must be kept to a minimum. 
Guidelines exceeding 8 000 words will only be considered for publication as a 
supplement to the SAMJ; the costs of which must be covered by sponsorship or 
advertising. The Editor reserves the right to determine the scheduling of 
supplements. Understandably, a delay in publication must be anticipated dependent 
upon editorial workflow. 
Manuscript preparation 
Refer to articles in recent issues for the presentation of headings and subheadings. If 
in doubt, refer to 'uniform requirements' - www.icmje.org. Manuscripts must be 
provided in UK English. 
Qualification, affiliation and contact details of ALL authors must be provided in the 
manuscript and in the online submission process. 
Abbreviations should be spelt out when first used and thereafter used consistently, 
e.g. 'intravenous (IV)' or 'Department of Health (DoH)'.
Scientific measurements must be expressed in SI units except: blood pressure 
(mmHg) and haemoglobin (g/dl). Litres is denoted with a lowercase 'l' e.g. 'ml' for 
millilitres). Units should be preceded by a space (except for %), e.g. '40 kg' and '20 
cm' but '50%'. Greater/smaller than signs (> and 40 years of age'. The same applies 
to ± and º, i.e. '35±6' and '19ºC'. 
Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160... 
Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
Round brackets (parentheses) should be used, as opposed to square brackets, which 
are reserved for denoting concentrations or insertions in direct quotes. 
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General formatting The manuscript must be in Microsoft Word or RTF document 
format. Text must be single-spaced, in 12-point Times New Roman font, and contain 
no unnecessary formatting (such as text in boxes, with the exception of Tables). 
 
Illustrations and tables 
If tables or illustrations submitted have been published elsewhere, the author(s) 
should provide consent to republication obtained from the copyright holder. 
Tables may be embedded in the manuscript file or provided as 'supplementary files'. 
They must be numbered in Arabic numerals (1,2,3...) and referred to consecutively in 
the text (e.g. 'Table 1'). Tables should be constructed carefully and simply for 
intelligible data representation. Unnecessarily complicated tables are strongly 
discouraged. Tables must be cell-based (i.e. not constructed with text boxes or tabs), 
and accompanied by a concise title and column headings. Footnotes must be 
indicated with consecutive use of the following symbols: * † ‡ § ¶ || then ** †† ‡‡ 
etc. 
Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 
1)'. Figure legends: Fig. 1. 'Title...' All illustrations/figures/graphs must be of high 
resolution/quality: 300 dpi or more is preferable, but images must not be resized to 
increase resolution. Unformatted and uncompressed images must be attached 
individually as 'supplementary files' upon submission (not solely embedded in the 
accompanying manuscript). TIFF and PNG formats are preferable; JPEG and PDF 
formats are accepted, but authors must be wary of image compression. Illustrations 




References must be kept to a maximum of 15. Authors must verify references from 
original sources. Only complete, correctly formatted reference lists will be accepted. 
Reference lists must be generated manually and not with the use of reference 
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between square brackets, e.g. These regulations are endorsed by the World Health 
Organization,[2] and others.[3,4-6] All references should be listed at the end of the 
article in numerical order of appearance in the Vancouver style (not alphabetical 
order). Approved abbreviations of journal titles must be used; see the List of Journals 
in Index Medicus. Names and initials of all authors should be given; if there are more 
than six authors, the first three names should be given followed by et al. First and 
last page, volume and issue numbers should be given. 
Wherever possible, references must be accompanied by a digital object identifier 
(DOI) link and PubMed ID (PMID)/PubMed Central ID (PMCID). Authors are 
encouraged to use the DOI lookup service offered by CrossRef. 
Journal references: Price NC, Jacobs NN, Roberts DA, et al. Importance of asking 
about glaucoma. Stat Med 1998;289(1):350-355. 
[http://dx.doi.org/10.1000/hgjr.182] [PMID: 2764753] 
Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. London: 
Butterworth, 1975:96-101. Chapter/section in a book: Weinstein L, Swartz MN. 
Pathogenic Properties of Invading Microorganisms. In: Sodeman WA jun, Sodeman 
WA, eds. Pathologic Physiology: Mechanisms of Disease. Philadelphia: WB Saunders, 
1974:457-472. 
Internet references: World Health Organization. The World Health Report 2002 - 
Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization, 2002. 
http://www.who.int/whr/2002 (accessed 16 January 2010). 
Other references (e.g. reports) should follow the same format: Author(s). Title. 
Publisher place: publisher name, year; pages. Cited manuscripts that have been 
accepted but not yet published can be included as references followed by '(in press)'. 
Unpublished observations and personal communications in the text must not appear 
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in the reference list. The full name of the source person must be provided for 
personal communications e.g. '...(Prof. Michael Jones, personal communication)'. 
 
PROOFS 
A PDF proof of an article may be sent to the corresponding author before 
publication to resolve remaining queries. At that stage, only typographical changes 
are permitted; the corresponding author is required, having conferred with his/her 
co-authors, to reply within 2 working days in order for the article to be published in 
the issue for which it has been scheduled. 
 
CHANGES OF ADDRESS 
Please notify the Editorial Department of any contact detail changes, including 
email, to facilitate communication. 
 
CPD POINTS 
Authors can earn up to 15 CPD CEUs for published articles. Certificates may be 
requested after publication of the article. 
 
CHARGES 
There is no charge for the publication of manuscripts. 
Please refer to the section on 'Guidelines' regarding the publication of supplements, 
where a charge may be applicable. 
 
Submission Preparation Checklist 
As part of the submission process, authors are required to check off their 
submission's compliance with all of the following items, and submissions may be 
returned to authors that do not adhere to these guidelines. 
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Chapter 2: Publication-ready manuscript 
Abstract 
Background 
Severe Retinopathy of Prematurity (ROP) can cause blindness. Prior to 2016, 
resource limitations precluded routine screening for ROP at Groote Schuur Hospital 
(GSH). Previous pilot studies at GSH found no patients ROP requiring treatment, 
however, improved preterm infant survival may affect the prevalence. 
Objectives 
To determine the prevalence and severity of ROP, describe potential risk factors and 
assess the feasibility of ROP screening. 
Method 
Infants with a birth weight (BW) of < 1251 g or gestational age (GA) < 31 weeks were 
screened from November 2012 to May 2013. 
Results 
Three hundred and thirteen ROP examinations were performed in 135 of 191 eligible 
infants. The mean GA and BW were 30.1 ± 1.9 weeks and 1056 ± 172 g respectively. 
ROP was diagnosed in 40 (29.6%) infants; eight (5.9%) had severe ROP and 2 
received laser treatment. Infants with ROP had a lower mean GA, 29.2 ± 1.6 vs. 30.5 
± 1.9 weeks (P<0.002) and lower mean BW, 988 ± 181 g vs. 1085 ± 160 g (P=0.001) 
than those without ROP. Infants < 1000 g had a 2.5 times higher risk of having ROP 
(95% CI 1.05-5.90, P=0.03). Blood transfusions (P<0.002) and late onset sepsis 
(P=0.024) were strongly associated with ROP. ROP screening was completed in 
91.1% (123/135) of infants. 
Conclusion 
The prevalence and severity of ROP has increased in GSH. The strong association 
with BW and GA suggests that infants with lower weights and gestational ages 
should be prioritized for screening in our resource limited setting.  
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Main Text 
Introduction 
Retinopathy of prematurity (ROP) is a preventable cause of visual impairment in 
premature neonates.[1] Screening and early treatment is important to prevent 
related morbidity. An increase in ROP has been reported in middle-income countries, 
as greater numbers of premature infants survive due to improved neonatal care but 
lack adequate monitoring when receiving oxygen therapy.[2] The ROP Working Group 
of South Africa has recommended guidelines for the prevention, screening and 
treatment of ROP for South Africa, based on international guidelines.[3] The United 
South African Neonatal Association, the Ophthalmological Society of South Africa 
and the South African Vitreoretinal Society have endorsed these recommendations, 
but resource limitations are acknowledged as a limiting factor in implementation of 
these guidelines. 
The Groote Schuur Hospital (GSH) neonatal unit provides tertiary care for over 500 
very low birth weight (VLBW) and extremely low birth weight (ELBW) premature 
infants from the West Metro region of the Western Cape per year. A study at GSH in 
1991 by Straker et al, as well as an unpublished study in 2001, did not detect any 
ROP requiring treatment.[4, 5] Based on these findings and resource constraints, an 
ROP screening service was not instituted.  
More recent data from other tertiary South African hospitals suggested that a review 
is required. Studies between 1995 and 2013 reported an incidence of ROP ranging 
from 16.3% to 31.1%.[6-9] The incidence of severe ROP varied from 4.3% to 7.1%, with 
no infants weighing more than 1250 g requiring treatment. These studies all 
reported infants requiring treatment for ROP. Based on these data, we secured 
funding to conduct a six-month pilot study.  The aims of the study were to: 1) 
determine the prevalence and severity of ROP in a prospective cohort of preterm 
infants; 2) describe the association of pre-specified potential risk factors; and 3) to 
assess the feasibility of screening for ROP in a relatively resource-limited setting.  
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Methods 
A prospective cohort study of a pilot ROP screening program was conducted at GSH 
from November 2012 to May 2013. The duration of the study was limited by the 
available funding for the support staff. This study was approved by the University of 
Cape Town Health Sciences Faculty Human Research Ethics Committee and conforms 
to the principles of the 2013 Declaration of Helsinki. 
Inclusion criteria 
 Birth weight (BW) < 1251 g OR
 Birth gestational age (GA) confirmed by Ballard score ≤ 31 weeks at birth
Exclusion criteria 
• Lethal congenital conditions
• Infants of parents who refused consent
Consent 
Written informed parental consent was obtained for ROP examination and inclusion 
into the study. Consent was obtained from the medical superintendent for infants 
being fostered or adopted.  
Medical management 
The International Liaison Committee on Resuscitation (ILCOR 2010) guideline was 
followed. Infants were monitored with pulse oximetry, targeting saturations of 
88-92%. Exclusive breast milk feeds were encouraged for all infants – donor breast
milk was variably available to infants weighing less than 1200 g. Cranial ultrasounds 
were performed in the first week of life and repeated at discharge, or earlier if 
indicated.  
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Screening ophthalmic examination 
A paediatric ophthalmologist examined infants once a week. The neonatal unit’s 
admissions book was reviewed daily to identify eligible infants. A register and diary 
was kept to facilitate the timing of examinations. The first examination occurred at 
4 weeks chronological age or at 32 weeks corrected GA, whichever occurred later. 
Examination was deferred in clinically unstable infants.  A research assistant was 
employed for the duration of the study to complete administration and assist during 
examinations. Cyclopentolate hydrochloride and phenylephrine hydrochloride drops, 
one drop every fifteen minutes up to a maximum of three, was instilled into each 
eye in preparation for screening. Benoxinate hydrochloride 0.4% was used for local 
anaesthetic. Inpatients were monitored as per standard practice in the neonatal 
unit. Outpatients were discharged once they were successfully fed post examination. 
The infants’ retinas were examined by binocular indirect ophthalmoscopy. The 
ophthalmologist determined follow up as per standard guidelines.[10] 
If infants were transferred, receiving hospitals were informed that screening needed 
to be completed. On discharge, appointments were communicated to parents and 
documented. Reminders were sent three days prior to appointments. If three 
consecutive appointments were missed, no further contact was attempted. 
However, if the research assistant was contacted, a booking was made for the next 
session.  
Infants were discharged from screening as per recommended SA guidelines.[3] Initial 
and subsequent follow up was done at the GSH neonatal unit. Infants requiring 
prolonged follow up were reviewed at the ophthalmology outpatient clinic at Red 
Cross War Memorial Children’s Hospital. A maximum of 20 patients were examined 
per session. 
Treatment of ROP 
Treatment was administered as per Early Treatment for Retinopathy of Prematurity 
Randomized Trial (ETROP) guidelines.[11] A retinal specialist performed laser 
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treatment in the neonatal unit within 72 hours of diagnosis. 
 
Data collection and statistics 
The following information was collected:  
1. Demographic details 
2. Clinical information: early (< 72hours post-delivery) or late (> 72 hours post-
delivery) onset of sepsis; intraventricular/ periventricular haemorrhage (grade 3 or 
4); type of enteral nutrition (in the first six weeks of life)  
3. Findings of screening examination: 
• Presence or absence of ROP 
• Grade of ROP if present (ICROP revisited)[12] 
• Findings at follow up examination 
• Need for ROP treatment 
Stata Version 12 was used for statistical analysis. Demographic and clinical data were 
presented with descriptive statistical methods. Comparative statistics were done on 
infants grouped according the presence of ROP as a primary outcome, infants with 
mild ROP and those with clinically significant ROP (CSROP). The presence of stage 3 
ROP or any stage of ROP with plus disease was classified as CSROP.  
Factors associated with different severity grades were described. The Chi square or 
Fisher’s exact tests were used for categorical comparisons, depending on the 
expected values. The Student’s t and the Wilcoxon rank sum tests were used for 
comparison of parametric and non-parametric continuous variables respectively. All 
statistical tests are 2-sided at alpha= 0.05. Multivariate analysis was performed on 
statistically significant risk factors (P value < 0.2). Multivariate analysis was done 
using a Poisson regression model with a robust error variance for relative risk. 
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Results 
Screening was performed in 135 of the 191 eligible infants. Figure 1 shows the 
derivation of the final dataset. The pre-specified perinatal characteristics of the 
cohort are shown in Table 1. The mean GA and weight at birth were 30.1 ± 1.9 weeks 
and 1056 ± 172 g respectively. Seventy-four infants were female (54.8%). Only black 
(57.0%) and coloured (42.9%) infants were represented in the sample. One infant 
had a family history of ROP.  
Table 2 shows the numbers of examinations per infant. In total, 313 examinations 
were performed; 38.5% of infants required one, 31.9% required two and 16.3% had 
four or more examinations. Three (2.2%) infants had 8 ROP examinations.  
The stages of ROP in the cohort, including infants in whom screening was not 
completed, are indicated in Table 3. ROP was diagnosed in 40 (29.6%) infants; eight 
(5.9%) had clinically significant ROP. No infants had stage 4 or 5 ROP. Stage 3 ROP 
occurred in one infant with a BW more than 1250 g, but regressed and did not 
require treatment. Two infants received laser treatment. Screening was completed 
in 91.1% (123/135). Twelve infants were lost to follow up. Of these, seven (58.3%) 
had ROP and two (16.7%) infants had CSROP. 
Table 4 shows comparisons of pre-specified potential risk factors. Infants with ROP 
had a lower mean GA and BW than those without ROP: 29.2 ± 1.6 vs. 30.5 ± 1.9 
weeks (P<0.002) and 988 ± 181 g vs. 1085 ± 160 g (P=0.001) respectively. Infants 
with ROP were more likely to have received a blood transfusion (P < 0.002), shown in 
Figure 2; to have late onset sepsis (P=0.024), shown in Figure 3; and to receive 
exclusive breast milk feeds (P=0.005).  
The comparison of potential risk factors in infants with mild ROP and CSROP is 
shown in Table 5 – there were no significant differences. The comparison of 
potential risk factors in infants with no ROP/mild ROP and infants with CSROP are 
shown in Table 6 – Infants delivered via caesarean section were less likely to develop 
CSROP (P=0.007). 
On multivariate analysis, the GA at birth was the only variable independently 
associated with ROP (RR 0.85; 95% CI 0.740-0.988; P=0.03). If GA was excluded, BW 
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(RR 0.99; 95% CI 0.997-0.999; P=0.03) and blood transfusions (RR 1.71; 95% CI 1.027-
2.859; P=0.03) were independently associated with ROP. ELBW infants had a 2.5 
times higher risk of having ROP than their larger counterparts (95% CI 1.05-5.90, 
P=0.03). The prevalence of ROP according to BW is described further in Figure 4. 
Discussion 
ROP occurred in 29.6% of the study cohort; 5.9% developed CSROP and two (1.5%) 
received laser treatment. Infants that required treatment weighed below 1250 g at 
birth. The prevalence in this study is significantly higher than in previous studies at 
GSH.[4, 5] Infrastructure and resources in the health care facilities referring to GSH 
have improved in the past two decades. Additionally, surfactant therapy and non-
invasive ventilation are more accessible, contributing to improved preterm 
survival.[13] Straker et al. reported an incidence of ROP of 19.2%, including all infants 
with a BW of less than 1500 g; 1.5% of infants developed severe ROP and no  infants 
required treatment.[4] However, infants in their study were small for gestational age. 
This study’s lower weight inclusion criteria with a potentially greater proportion of 
less mature infants being included, may explain the higher prevalence of ROP. 
Growth restriction was not specifically assessed. Richards reported an overall ROP 
incidence of 3.6% in infants weighing less than 1500 g increasing to 14.5% in infants 
less than 28 weeks gestation at birth, with no infants requiring treatment.[5] 
However, infants were assessed at 6 weeks chronological age and then again at term 
if no ROP was initially detected, potentially missing infants who developed ROP and 
then regressed before review - repeat examinations in our study occurred more 
frequently, every 2 to 3 weeks. In Richards’ study, 73% of infants attended follow-up, 
but only 44% of infants less than 28 weeks were seen more than once.[5] The higher 
rate of ROP in our study may be due to the higher proportion attending follow-up.  
Other South African studies show a significant prevalence of ROP. In 1997, Gilbert et 
al. found that ROP accounted for 10.6% of blindness.[13] In 1995, Kirsten et al. 
showed a ROP prevalence of 31.1% in mechanically ventilated VLBW infants, with 
7.1% stage 3 or worse ROP, likely due to the exclusive inclusion of mechanically 
ventilated infants.[8] In 2002, Delport et al. found an incidence of ROP of 24.5% at 
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Kalafong Hospital in VLBW infants - only two infants with a BW above 1250 g 
developed ROP, similar to our findings.[7] The incidence of severe ROP was 3.2% in 
infants weighing below 1250 g at birth, with 4.3% requiring treatment, slightly higher 
than in our study. In a study in Johannesburg in 2006, Mayet et al. showed a 16.3% 
prevalence of ROP in VLBW infants – 1.6% of infants received treatment.[6] As in 
other South African studies, the majority of infants with ROP weighed less than 
1250_g and no infants weighing more than 1250 g required treatment.[6] The higher 
follow up rate in our study may account for the apparent higher ROP prevalence. A 
study at Tygerberg hospital in 2013, reported an ROP prevalence of 21.8% in ELBW 
infants, with 4.4% of infants developing CSROP.[9] The percentage of infants needing 
treatment was the same as in our study. Although the BW and GA criteria were 
lower than the inclusion criteria we used, the prevalence of ROP and CSROP were 
significantly lower, possibly explained by the exclusion of infants mechanically 
ventilated in the first week of life. 
Infants in our study with ROP had a lower mean GA and mean BW, similar to other 
South African and certain middle-income country studies.[2, 6, 7, 9, 14, 15] On multivariate 
analysis, only GA was independently associated with ROP, however GA assessment 
may be inaccurate as it was based on antenatal ultrasound, which often occurred 
only after 20 weeks gestation, and/or Ballard score which is only accurate to 
± 2 weeks. When GA is removed from the analysis, lower BW remains an 
independent risk factor for ROP. 
Infants with ROP were more likely to have received a blood transfusion and, as in 
other studies, more likely to have late onset sepsis.[15] Small numbers of these 
patients due to restrictive transfusion policies and low incidence of sepsis prevented 
meaningful interpretation of their risk to develop CSROP.  
Contrary to other studies citing a protective role or no effect of breast milk,[16-18] 
infants in our study who received exclusive breast milk feeds were more likely to 
have ROP. Unit policy at the time restricted the use of donor breast milk feeds to 
infants < 1200 g.  The use of exclusive breast milk feeding was therefore associated 
with lower birth weight.  
Previous studies have found a low occurrence of severe ROP in black patients or 
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darkly pigmented fundi.[6, 19] Interpretation of this risk factor was not possible, as 
only black and coloured infants were represented in our cohort. Genetics may play a 
role in developing ROP.[20] Only one infant had a family history of ROP, which 
probably reflects the lack of ROP screening services in the public health sector. There 
were no significant differences in maternal risk factors, place of birth, mode of 
delivery and need for resuscitation between the groups with and without ROP. 
The level of respiratory support, the need for oxygen therapy, the occurrence of 
apnoea, early sepsis or severe intraventricular haemorrhage was also similar 
between infants with and without ROP.  
The role of oxygen has been well described in the development of ROP.[1] No 
statistical significance was found when comparing oxygen concentration and 
duration of oxygen received in the two groups. This finding may be due to strict 
saturation targeting in infants receiving oxygen therapy. One infant who had never 
received oxygen therapy developed ROP – prematurity may be a more significant 
factor than exposure to oxygen therapy.[21] 
When analyzing risk factors in infants with mild/no ROP and CSROP, infants delivered 
via caesarean section were less likely to have CSROP. The association could be 
related the potential for greater exposure to both hypoxia and hyperoxia in vaginal 
deliveries. Moreover, patients with pre-eclamptic toxaemia (PET) may be more likely 
to deliver via caesarean section. A negative correlation between ROP and PET has 
been described.[22]  The association of delivery via caesarean section and decreased 
incidence of ROP may be due to chance. The small numbers in our study precluded 
further analysis. 
Successful ROP screening required extensive resources. A research assistant was 
employed to assist with administrative tasks, preparation for screening and also 
assisted during examination. ROP examination was only available at GSH, which 
posed the potential problem of overcrowding with the associated risks. If transfer 
needed to be effected, logistical challenges faced included ambulance services’ 
availability and accommodation in a tertiary service with limited bed capacity when 
transfer back for ROP examination was required. Outpatient facilities, staffing and 
equipment had to be provided when infants were discharged prior to completion of 
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screening. 
Laser treatment was performed in the neonatal unit within 72 hours of diagnosis for 
infants requiring treatment. Challenges included the provision of theatre facilities in 
the neonatal unit, equipment and staffing, including the availability of a retinal 
surgeon. Centralized care must be considered when infants require treatment of 
ROP. Theatre facilities need to accommodate the specific needs of preterm infants. 
Facilities for treatment, in addition to skilled clinicians for ophthalmic examination 
and treatment of ROP, should be available before embarking on a screening 
program.  
The follow up rate in this study was 91.1%. Study funding ensured that resources 
were allocated to facilitate this. Parents were well informed, aware of follow up 
appointments and were contacted when appointments were missed. Transport costs 
were reimbursed if required. Despite this, 12 infants were lost to follow up, including 
two with CSROP. The lost to follow-up rate is similar to that of van der Merwe et al. 
(13.8%), significantly lower than in other South African studies.[9]  The major strength 
of this study was the high enrolment and follow up rates, which support the validity 
of the sample. All screening was performed by two ophthalmologists- this ensured 
consistency in reporting and management of ROP findings. The major limitation of 
the study was the potential inaccuracy of gestational age assessment, limiting the 
use of this parameter in clinical guidelines for screening. Additionally, all race groups 
were not represented in the study population. Although the ROP prevalence is 
similar to other South African studies, it may be different if all race groups were 
represented in the sample. The use of WINROP®, an online surveillance system that 
identifies infants at risk of developing severe ROP, would have been useful given 
resource constraints.[23] Due to limited staffing and funding, we were not able to 
explore this tool.  Further studies comparing the incidence of ROP in various 
provincial hospitals, possibly using WINROP®, would be of value. 
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Conclusion 
The prevalence of ROP in this study is similar to that in other reported South African 
studies, which do not reflect the ‘third epidemic’ of ROP. No infants over 1250 g 
required laser treatment. The independent association of ROP with birth weight and 
the absence of treatment requiring ROP in the larger infants suggest that infants 
with lower birth weights should be prioritized for screening in our resource-limited 
setting. It was feasible to screen for ROP using the criteria in our study, but 
additional funded nursing and administrative assistance, skilled personnel, laser 
treatment, theatre facilities within or outside the neonatal unit, as well as neonatal 
intensive care, had to be readily accessible to infants requiring treatment. ROP 
screening has been implemented at GSH based on the study findings. If broader 
screening criteria were applied, further resources such as medical staffing and 
facilities would need to be made available. However, if appropriate oxygen targets 
are in place, the yield of ROP requiring treatment in larger and/or more mature 
infants is likely to be very low. 
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Figure 1: Derivation of the final data set 
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Figure 2: Incidence of ROP in infants receiving blood transfusions (n=135) 
Figure 3: Incidence of ROP in infants with late onset sepsis (n=135) 
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Figure 4: Incidence of ROP in birth weight categories (n=135) 
Page | 41  
Table 1: Perinatal characteristics of the cohort n = 135 
Characteristics n (%) /mean (+/-SD) / median (IQR) 
Infant characteristics 
Birth weight (g) 1056 (172) 
Gestational Age (weeks) 30.1 (1.9) 
Race – Black 77 (57.0) 
– Coloured 58 (43.0) 
Female gender 74 (54.8) 
Family history of ROP 1 (0.7) 
Maternal history 
Maternal VDRL positive 2 (1.5) 
Maternal HIV positive 22 (16.3) 
Maternal medication use 58 (43.0) 
Cigarettes/ tik /alcohol use 16 (11.9) 
Illness 73 (54.9) 
Birth and resuscitation history 
Out born 10 (7.4) 
Mode of delivery- C/S 95 (71.1) 
Apgar score (1 minute) † 7 (4-8) 
Apgar score (5minutes) † 9 (7-9) 
Resuscitation required †† 85 (64.9) 
Oxygen administered 103 (76.3) 
Facemask/ T-piece ventilation †† 85 (64.9) 
Endotracheal intubation †† 13 (9.9) 
Chest compressions †† 26 (19.9) 
Neonatal period 
Respiratory support 
O2 therapy 122 (90.4) 
CPAP/ HHFNC/ nasal cannula O2 95 (70.4) 
Mechanical ventilation 27 (20.0) 
Duration of O2 therapy (days) 5 (2-10) 
Highest concentration of O2 
received 
0.3 (0.25-0.37) 
Surfactant 40 (29.6) 
Apnoea 37 (27.4) 
Blood transfusion 28 (20.7) 
Sepsis-early 1 (0.7) 
Sepsis-late 7 (5.2) 
IVH (grade 3 or 4) ††† 4 (3.0) 
Exclusive breast milk feeds 50 (37.0) 
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†
 n = 133 
††
 n = 131 
†††
n = 132 
CPAP = Continuous Positive Airway Pressure 
C/S = Caesarean Section 
g = grams 
HHFNC = Humidified High Flow Nasal Cannula 
HIV = Human Immunodeficiency Virus 
IVH = Intraventricular haemorrhage 
n = number 
02 = Oxygen 
ROP = Retinopathy of Prematurity 
VDRL = Venereal Disease Research Laboratory 
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Table 2: Number of ROP examinations per infant, n= 135 
 
Number of examinations Number of infants, n (%) 
1 52 (38.5) 
2 43 (31.9) 
3 18 (13.3) 
4 7 (5.2) 
5 5 (3.7) 
6 5 (3.7) 
7 2 (1.5) 
8 3 (2.2) 
 
n = number 






Table 3: Prevalence of different stages of ROP (including infants lost to follow up) 
 
Stage of ROP, n (%) n=135 (100) Lost to follow up, n=12 
(100) 
No ROP 95 (70.4) 5 (41.7) 
ROP 40 (29.6) 7 (58.3) 
Stage 3 or plus disease 8 (5.9) 2 (16.7) 
Stage 4 or 5 0 (0.0) 0 (0.0) 
Laser treatment 2 (1.5) - 
 
n = number 
ROP= Retinopathy of Prematurity 
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Table 4: Potential risk factors in No ROP (n=95) compared to ROP (n=40) 
Potential risk factors No ROP n (%)/ mean 
(SD)/ median (IQR) 





Birth weight (g) 1084 (±160) 988 (±931) 0.002 
Gestational Age 
(weeks) 
30.5 (±1.9) 29.2 (±1.6) <0.001 
Race – Black 58 (61.0) 19 (47.5) 0.146 
– Coloured 37 (39.0) 21 (52.5) 
Female gender 50 (52.6) 24 (60.0) 0.432 




1 (1.1) 1 (2.5) 0.506* 
Maternal HIV 
positive 
15 (15.8) 7 (17.5) 0.806 
Maternal medication 
use 
39 (41.1) 19 (47.5) 0.490 
Cigarettes/ tik 
/alcohol use 
10 (10.5) 6 (15.0) 0.377* 
Illness 51 (54.3) 22 (56.4) 0.820 
Birth and resuscitation 
history 
Out born 7 (7.4) 3 (7.5) 1.000* 
Mode of delivery- 
C/S 
73 (76.8) 23 (57.5) 0.024 
Apgar score (1 
minute) † 
7 (4-8) 7 (3-8) 0.796** 
Apgar score 
(5minutes) † 
9 (7-9) 9 (7-9) 0.775** 
Resuscitation 
required†† 
61 (66.3) 24 (61.5) 0.601 
Oxygen administered 74 (77.9) 29 (72.5) 0.501 
Facemask/ T-piece 
ventilation†† 
61 (66.3) 24 (61.5) 0.601 
Endotracheal 
intubation†† 
6 (6.3) 7 (17.5) 0.132 
Chest 
compressions†† 
15 (15.8) 11 (27.5) 0.288 
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Neonatal period 
Respiratory support 
O2 therapy 85 (89.5) 37 (92.) 0.755* 
CPAP/ HHFNC/ nasal 
cannula O2 
66 (69.5) 29 (72.50) 0.725 
Mechanical 
ventilation 
19 (20) 8 (20) 1.000* 
Duration of O2 
therapy (days) 
4 (2-8) 5.5 (2-14) 0.360** 
Highest 
concentration of O2 
received (FiO2) 
0.3 (0.25-0.4) 0.3 (0.25-0.35) 0.859** 
Surfactant 27 (28.4) 13 (32.5) 0.636 
Apnoea 24 (25.3) 13 (32.5) 0.389 
Blood transfusion 12 (12.6) 16 (40.0) <0.001 
Sepsis-early 0 (0.0) 1 (2.5) 0.122 
Sepsis-late 2 (2.1) 5 (12.5) 0.024* 
IVH (grade 3 or 4) ††† 4 (4.2) 0 (0.0) 0.553* 











CPAP=Continuous Positive Airway Pressure 
C/S = Caesarean Section 
g = grams 
HHFNC = Humidified High Flow Nasal Cannula 
HIV = Human Immunodeficiency Virus 
IQR = interquartile range 
IVH = Intraventricular haemorrhage 
n = number  
02 = Oxygen 
ROP= Retinopathy of Prematurity 
SD = standard deviation 
VDRL = Venereal Disease Research Laboratory 
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Table 5: Potential risk factors Mild ROP (n=32) compared to CSROP (n=8) 
Potential risk factors Mild ROP n (%)/ 
mean (SD)/ median 
(IQR) 





Birth weight (g) 984 (± 185) 1006 (± 171) 0.769 
Gestational Age 
(weeks) 
29.2 (± 1.6) 29.4 (± 1.3) 0.755 
Race – Black 17 (53.1) 2 (25.0) 0.154 
– Coloured 15 (46.9) 6 (75.0) 
Female gender 20 (62.5) 4 (50.0) 0.690* 




1 (3.1) 0 (0.0) 1.000* 
Maternal HIV 
positive 
6 (18.8) 1 (12.5) 1.000* 
Maternal medication 
use 
17 (53.1) 2 (25.0) 0.241* 
Cigarettes/ tik 
/alcohol use 
4 (12.5) 2 (25.0) 0.414* 
Illness 20 (35.5) 2 (25.0) 0.059* 
Birth and resuscitation 
history 
Out born 2 (6.3) 1 (12.5) 0.498* 
Mode of delivery- 
C/S 
21 (65.6) 2 (25.0) 0.053* 
Apgar score (1 
minute) 
7 (3-8) 7 (3-9) 0.891** 
Apgar score 
(5minutes) 
9 (7-9) 9 (6-10) 0.729** 
Resuscitation 
required† 
20 (62.5) 4 (50.0) 0.749* 
Oxygen administered 24 (75.0) 5 (62.5) 0.660* 
Facemask/ T-piece 
ventilation† 
20 (62.5) 4 (50.0) 0.749* 
Endotracheal 
intubation† 
6 (18.8) 1 (12.5) 1.000* 
Chest compressions† 8 (25.0) 3 (37.5) 0.731* 
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Neonatal period 
Respiratory support 
O2 therapy 30 (93.8) 7 (87.5) 0.498* 
CPAP/ HHFNC/ nasal 
cannula O2 
22 (68.8) 7 (87.5) 0.405* 
Mechanical 
ventilation 
8 (25.0) 0 (0.0) 0.173** 
Duration of O2 
therapy (days) 
5 (2-19.5) 8.5 (3.5-10.5) 0.786** 
Highest 
concentration of O2 
received (FiO2) 
††
0.3 (0.25-0.35) 0.3 (0.3-0.35) 0.388** 
Surfactant 11 (34.4) 2 (25.0) 1.000* 
Apnoea 9 (28.1) 4 (50.0) 0.400* 
Blood transfusion 14 (43.8) 2 (25.0) 0.439 
Sepsis-early 1 (3.1) 0 (0.0) 1.000* 
Sepsis-late 4 (12.5) 1 (12.5) 1.000* 
IVH (grade 3 or 4) 1 (3.1) 0 (0.0) 1.000* 
Exclusive breast milk feeds 18 (56.3) 4 (50.0) 1.000* 
† 
n = 39 
†† 





CPAP=Continuous Positive Airway Pressure 
C/S = Caesarean Section 
g = grams 
HHFNC = Humidified High Flow Nasal Cannula 
HIV = Human Immunodeficiency Virus 
IQR = interquartile range 
IVH = Intraventricular haemorrhage 
n = number  
02 = Oxygen 
ROP= Retinopathy of Prematurity 
SD = standard deviation 
VDRL = Venereal Disease Research Laboratory 
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Table 6: Potential risk factors No/Mild ROP (n=127) compared to CSROP (n=8) 
Potential risk factors No/Mild ROP n (%)/ 
mean (SD)/ median 
(IQR) 





Birth weight (g) 1059 (±172) 1006 (±171) 0.391 
Gestational Age 
(weeks) 
30.2 (±1.9) 29.4 (± 1.3) 0.260 
Race – Black 75 (59.1) 2 (25.0) 0.074* 
– Coloured 52 (40.9) 6 (75.0) 
Female gender 70 (55.1) 4 (50.0) 1.000* 




2 (1.6) 0 (0.0) 1.000* 
Maternal HIV 
positive 
21 (16.5) 1 (12.5) 1.000* 
Maternal medication 
use 
56 (44.1) 2 (25.0) 0.466* 
Cigarettes/ tik 
/alcohol use 
14 (11.1) 2 (25.0) 0.292* 
Illness 71 (56.8) 2 (25.0) 0.140* 
Birth and resuscitation 
history 
Out born 9 (7.1) 1 (12.5) 0.469* 
Mode of delivery- 
C/S 
94 (74.1) 2 (25.0) 0.007* 
Apgar score (1 
minute) † 
7 (4-8) 7 (3-9) 0.833** 
Apgar score 
(5minutes) † 
9 (7-9) 9 (6-10) 0.661** 
Resuscitation 
required†† 
81 (63.8) 4 (50.0) 0.571* 
Oxygen administered 98 (77.2) 5 (62.5) 0.394* 
Facemask/ T-piece 
ventilation†† 
81 (63.8) 4 (50.0) 0.571* 
Endotracheal 
intubation†† 
12 (9.5) 1 (12.5) 0.670* 
Chest 
compressions†† 
23 (18.1) 3 (37.5) 0.371* 
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Neonatal period 
Respiratory support 
O2 therapy 115 (90.5) 7 (87.5) 0.565* 
CPAP/ HHFNC/ nasal 
cannula O2 
88 (69.3) 7 (87.5) 0.435* 
Mechanical 
ventilation 
27 (21.3) 0 (0.0) 0.357* 
Duration of O2 
therapy (days) 
5 (2-10) 9 (4-10) 0.418** 
Highest 
concentration of O2 
received (FiO2) 
‡
0.3 (0.25-0.38) 0.3 (0.3-0.35) 0.582** 
Surfactant 38 (29.9) 2 (25.0) 1.000* 
Apnoea 33 (26.0) 4 (50.0) 0.214* 
Blood transfusion 26 (20.5) 2 (25.0) 0.670* 
Sepsis-early 1 (0.8) 0 (0.0) 1.000* 
Sepsis-late 6 (4.7) 1 (12.5) 0.355* 
IVH (grade 3 or 4) ‡‡ 4 (3.2) 0 (0.0) 1.000* 
Exclusive breast milk feeds 46 (36.2) 4 (50.0) 0.534* 
†
 n = 133 
††
 n = 131 
‡
 n = 122 
‡‡
 n = 132 
*Fisher’s exact ** Wilcoxon rank-sum 
CPAP=Continuous Positive Airway Pressure 
C/S = Caesarean Section 
g = grams 
HHFNC = Humidified High Flow Nasal Cannula 
HIV = Human Immunodeficiency Virus 
IQR = interquartile range 
IVH = Intraventricular haemorrhage 
n = number  
02 = Oxygen 
ROP= Retinopathy of Prematurity 
SD = standard deviation 
VDRL = Venereal Disease Research Laboratory 
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